ASH 2021 | Safety and efficacy of blinatumomab and inotuzumab ozogamicin in multiple relapsed ALL
Cristina Papayannidis, MD, PhD, University of Bologna, Bologna, discusses the results of a study which investigated the safety and efficacy of blinatumomab and inotuzumab ozogamicin in the treatment of multiple relapsed acute lymphoblastic leukemia (ALL). This was a real-life multi-center analysis, which aimed to describe the outcome of patients treated with these two immunotherapeutic agents. As this patient subset often has a very poor outcome, the results from this study provide useful information on how to improve the standard of care for multiple relapsed ALL. Dr Papayannidis discusses the results obtained in this analysis, including complete remission, death rates, overall survival and adverse events, and the benefit of combining blinatumomab and inotuzumab ozogamicin with allogeneic stem cell transplant in the future. This interview took place at the 63rd ASH Annual Meeting and Exposition congress, Atlanta, GA, 2021.
Disclosures
Amgen, Pfizer: Advisory Board and Honoraria
